Table S4.
Univariate and multivariate Cox regression analyses of PFS and CSS including chemotherapy received before and after propensity matching
| Clinical parameter | Unmatched (complete) dataset | Propensity score-matched (1:1) dataseta | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analyses | Multivariate analyses | Univariate analyses | Multivariate analyses | ||||||
| HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| PFS | Male | 1.169 (0.879−1.556) | 0.284 | 1.017 (0.761−1.359) | 0.911 | 0.776 (0.508−1.187) | 0.243 | 0.709 (0.457−1.102) | 0.126 |
| Age >60 years | 1.678 (1.263−2.228) | <0.001 | 1.409 (1.044−1.903) | 0.025 | 1.270 (0.811−1.987) | 0.296 | 1.230 (0.774−1.955) | 0.380 | |
| Stage III−IV | 3.311 (2.285−4.797) | <0.001 | 2.163 (1.439−3.249) | <0.001 | 2.717 (1.577−4.681) | <0.001 | 1.794 (0.967−3.327) | 0.064 | |
| ECOG PS 2−4 | 2.088 (1.486−2.935) | <0.001 | 1.447 (1.006−2.081) | 0.046 | 1.763 (1.067−2.914) | 0.027 | 1.354 (0.786−2.332) | 0.275 | |
| Extranodal sites >1 | 1.897 (1.415−2.545) | <0.001 | 1.176 (0.856−1.614) | 0.317 | 2.280 (1.476−3.522) | <0.001 | 1.732 (1.046−2.868) | 0.033 | |
| Non-GCB | 1.904 (1.384−2.619) | <0.001 | 1.660 (1.203−2.290) | 0.002 | 1.601 (0.985−2.603) | 0.058 | 1.857 (1.128−3.056) | 0.015 | |
| B symptoms | 1.912 (1.440−2.538) | <0.001 | 1.235 (0.909−1.677) | 0.177 | 1.673 (1.094−2.557) | 0.017 | 1.091 (0.659−1.806) | 0.735 | |
| LDH >ULN (271U/L) | 3.041 (2.282−4.052) | <0.001 | 2.048 (1.502−2.793) | <0.001 | 2.459 (1.604−3.770) | <0.001 | 1.808 (1.080−3.024) | 0.024 | |
| Treatmentsb | 0.961 (0.755−1.222) | 0.743 | 0.926 (0.721−1.191) | 0.550 | 1.057 (0.753−1.484) | 0.747 | 0.936 (0.634−1.383) | 0.741 | |
| Diabetic | 1.744 (1.259−2.417) | 0.001 | 1.457 (1.037−2.047) | 0.030 | 1.607 (1.045−2.470) | 0.031 | 1.672 (1.078−2.592) | 0.022 | |
| CSS | Male | 0.948 (0.669−1.344) | 0.764 | 0.817 (0.573−1.164) | 0.263 | 0.721 (0.448−1.161) | 0.179 | 0.657 (0.404−1.069) | 0.091 |
| Age ≥60 years | 1.867 (1.316−2.647) | <0.001 | 1.500 (1.035−2.175) | 0.032 | 1.388 (0.835−2.308) | 0.206 | 1.320 (0.774−2.250) | 0.308 | |
| Stage III−IV | 3.443 (2.135−5.551) | <0.001 | 2.340 (1.389−3.942) | 0.001 | 2.676 (1.433−4.998) | 0.002 | 1.722 (0.842−3.525) | 0.137 | |
| ECOG PS 2−4 | 2.730 (1.839−4.053) | <0.001 | 1.854 (1.213−2.835) | 0.004 | 2.178 (1.266−3.746) | 0.005 | 1.614 (0.890−2.929) | 0.115 | |
| Extranodal sites >1 | 1.976 (1.382−2.825) | <0.001 | 1.179 (0.802−1.734) | 0.402 | 2.742 (1.698−4.429) | <0.001 | 1.901 (1.094−3.303) | 0.023 | |
| Non-GCB | 1.896 (1.280−2.810) | 0.001 | 1.650 (1.108−2.457) | 0.014 | 1.816 (1.036−3.184) | 0.037 | 1.990 (1.110−3.567) | 0.021 | |
| B symptoms | 1.757 (1.241−2.489) | 0.002 | 1.054 (0.723−1.538) | 0.784 | 1.539 (0.956−2.477) | 0.076 | 0.934 (0.532−1.640) | 0.812 | |
| LDH >ULN (271U/L) | 3.341 (2.336−4.778) | <0.001 | 2.156 (1.462−3.178) | <0.001 | 2.621 (1.616−4.251) | <0.001 | 1.851 (1.034−3.313) | 0.038 | |
| Treatments | 1.081 (0.810−1.442) | 0.597 | 1.068 (0.794−1.436) | 0.665 | 1.192 (0.824−1.724) | 0.351 | 1.059 (0.701−1.600) | 0.784 | |
| Diabetic | 2.713 (1.874−3.928) | <0.001 | 2.258 (1.535−3.324) | <0.001 | 2.145 (1.306−3.523) | 0.003 | 2.052 (1.239−3.397) | 0.005 | |
Notes: aPropensity score-matched (1:1, 109 pairs) analyses were performed with a small caliper of 0.1 for matching potential confounders including sex, age, stage, ECOG PS, extranodal site(s), Hans classification, symptoms and LDH level. bTreatments referred to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone), DA-EPOCH+R (dose-adjusted (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) plus rituximab), R-CHOP like regimens, and R-mini CHOP (rituximab combined with low-dose CHOP). p-values in bold < 0.05.
Abbreviations: PFS, progression-free survival; CSS, cancer-specific survival; ECOG, Eastern Cooperative Oncology Group; PS, performance status; GCB germinal center B-cell; LDH, lactate dehydrogenase; ULN, upper limit of normal.